TPST
Price:
$0.9055
Market Cap:
$39.52M
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.[Read more]
Industry
Biotechnology
IPO Date
2012-11-12
Stock Exchange
NASDAQ
Ticker
TPST
According to Tempest Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 35.14M. This represents a change of -44.72% compared to the average of 63.56M of the last 4 quarters.
The mean historical Enterprise Value of Tempest Therapeutics, Inc. over the last ten years is 120.27M. The current 35.14M Enterprise Value has changed 2.82% with respect to the historical average. Over the past ten years (40 quarters), TPST's Enterprise Value was at its highest in in the December 2014 quarter at 1.20B. The Enterprise Value was at its lowest in in the June 2021 quarter at -38993670.24.
Average
120.27M
Median
4.71M
Minimum
-60460032.00
Maximum
995.04M
Discovering the peaks and valleys of Tempest Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.08%
Maximum Annual Enterprise Value = 995.04M
Minimum Annual Increase = -413.58%
Minimum Annual Enterprise Value = -60460032.00
Year | Enterprise Value | Change |
---|---|---|
2023 | 49.26M | 1.08% |
2022 | 4.17M | -131.37% |
2021 | -13279200.16 | -13.65% |
2020 | -15379159.00 | -146.05% |
2019 | 33.39M | -155.23% |
2018 | -60460032.00 | 266.82% |
2017 | -16482047.80 | -413.58% |
2016 | 5.26M | -97.62% |
2015 | 221.20M | -77.77% |
2014 | 995.04M | 426.71% |
The current Enterprise Value of Tempest Therapeutics, Inc. (TPST) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
13.38M
5-year avg
11.63M
10-year avg
120.27M
Tempest Therapeutics, Inc.’s Enterprise Value is greater than Indaptus Therapeutics, Inc. (2.92M), less than Rezolute, Inc. (276.11M), greater than Comera Life Sciences Holdings, Inc. (-1587053.00), greater than Forte Biosciences, Inc. (7.03M), less than Sana Biotechnology, Inc. (551.82M), less than Olema Pharmaceuticals, Inc. (468.89M), less than Cullinan Oncology, Inc. (630.54M), less than aTyr Pharma, Inc. (138.44M), less than Zentalis Pharmaceuticals, Inc. (229.32M), less than Lyell Immunopharma, Inc. (216.40M), less than Monte Rosa Therapeutics, Inc. (439.72M), less than Theseus Pharmaceuticals, Inc. (138.26M), less than Revolution Medicines, Inc. (9.43B), less than ZIVO Bioscience, Inc. (73.95M), greater than RenovoRx, Inc. (21.40M), less than Ikena Oncology, Inc. (45.73M), greater than Catalyst Biosciences, Inc. (19.42M), greater than Akari Therapeutics, Plc (17.47M), less than Armata Pharmaceuticals, Inc. (138.55M), less than Anebulo Pharmaceuticals, Inc. (36.46M), greater than Scopus BioPharma Inc. (-111950.00), greater than Processa Pharmaceuticals, Inc. (15.28K),
Company | Enterprise Value | Market cap |
---|---|---|
2.92M | $10.20M | |
276.11M | $284.50M | |
-1587053.00 | $9.22K | |
7.03M | $23.39M | |
551.82M | $582.73M | |
468.89M | $503.07M | |
630.54M | $730.17M | |
138.44M | $131.12M | |
229.32M | $230.19M | |
216.40M | $265.26M | |
439.72M | $521.60M | |
138.26M | $181.50M | |
9.43B | $9.55B | |
73.95M | $74.08M | |
21.40M | $30.96M | |
45.73M | $82.52M | |
19.42M | $19.42M | |
17.47M | $18.72M | |
138.55M | $81.41M | |
36.46M | $37.86M | |
-111950.00 | $12.63K | |
15.28K | $2.81M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tempest Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Tempest Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Tempest Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Tempest Therapeutics, Inc. (TPST)?
What is the 3-year average Enterprise Value for Tempest Therapeutics, Inc. (TPST)?
What is the 5-year average Enterprise Value for Tempest Therapeutics, Inc. (TPST)?
How does the current Enterprise Value for Tempest Therapeutics, Inc. (TPST) compare to its historical average?